Flexible cannulas safest for akinesia

Article

Flexible cannulas are safest for akinesia and anaesthesia in the latest comparison study on sub-Tenon cannulas.

Flexible cannulas are safest for akinesia and anaesthesia in the latest comparison study on sub-Tenon cannulas.

A team led by Dr Waleed Riad, King Khaled Specialist Eye Hospital, Riyadh, Saudi Arabia, conducted a prospective, blind, randomized comparison between metal posterior, flexible posterior and flexible medium sub-Tenon cannulas forakinesia and anaesthesia.

The investigation included 159 patients who underwent cataract surgery under sub-Tenon block. All patients received a combination of bupivacaine and lidocaine with hyaluronidase.

Patients were divided into three groups. Group 1 received a metal posterior sub-Tenon cannula, group 2 had a flexible posterior sub-Tenon cannula and group 3 had a flexible medium sub-Tenon cannula. The outcome measures included pain during injection, akinesia, anesthesia, and complications.

Two minutes after injection the akinesia score, superior oblique muscle activity, lid movements and pain during injection was significantly lower in group 1. However, after four, six, eight and ten minutes there was no significant difference between cannulas.

Intraoperative pain was low for all groups but chemosis was significantly lower in group 2 and was found to be safer than the rigid cannulas.

The abstract can be found in the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.